Actively Recruiting

Phase Not Applicable
Age: 18Years - 40Years
All Genders
NCT06522984

Fractional Erbium YAG Laser vs Intradermal and Systemic Tranexamic Acid

Led by Egymedicalpedia · Updated on 2024-07-26

45

Participants Needed

1

Research Sites

53 weeks

Total Duration

On this page

Sponsors

E

Egymedicalpedia

Lead Sponsor

A

Aswan University

Collaborating Sponsor

AI-Summary

What this Trial Is About

Melasma is a common acquired disorder of hyperpigmentaion caused by increased melanin production by melanocytes. Melasma is a name derived from the Greek word melas meaning black.It is characterized by the appearance of brownish or grayish symmetrical patches on sun-exposed skin, most commonly on the face. Compared to men, women are more likely to be affected.

CONDITIONS

Official Title

Fractional Erbium YAG Laser vs Intradermal and Systemic Tranexamic Acid

Who Can Participate

Age: 18Years - 40Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients of both sexes with melasma
Not Eligible

You will not qualify if you...

  • Pregnancy
  • Lactation
  • Use of oral contraceptive pills or phototoxic drugs within 1 month prior to study
  • History of thrombosis or abnormal bleeding
  • Known allergy to tranexamic acid or hydroquinone
  • Endocrine diseases

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Aswan University hospitals

Aswān, Egypt

Actively Recruiting

Loading map...

Research Team

H

Heba Allah Mohamed Mustafa, Resident

CONTACT

M

Moustafa Adam Ali El Taieb, professor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here